Figure 3: PS341 suppresses the epithelial-mesenchymal transition of HCC and CRC cells.
From: PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway
(a) PS341 reverses the EMT transition induced by TGF-β1 in HCC and CRC cells. Scale bar = 25 μm. (b) The RT-PCR analysis of the mRNA expression of ECAD, NCAD, VIM, ZEB1 CD44 and POU5F1 in HCC and CRC cells with TGF-β1 and PS341 treatment. (c) The PCR analysis of the mRNA expression of the epithelial marker E-cadherin and the mesenchymal marker N-cadherin was carried out in HCC and CRC cells with TGF-β1 and PS341 treatment. (d) Protein expression levels of E-cadherin and N-cadherin were carried out in HCC and CRC cells with TGF-β1 and PS341 treatment. (e) PS341 suppresses the proliferation and metastasis of HepG2 and HT29 cancer cells in the peritoneal spreading mice models. 2 × 106 luciferase-expressing HepG2 and HT29 cancer cells were injected intraperitoneally into NOD/SCID mice with the administration of PS341 or DMSO twice a week, and the tumor cells were monitored once a week (n = 5). The whole assay was repeated three times. Data are displayed as mean ± SD. TGF-β: TGF-β1. The full-length blots/gels are presented in Supplementary Figs 1–3. *P < 0.05, **P < 0.01.
